Table 1.
Outcomes of 1419 patients in the N9741 trial data, overall and by treatment arm, corresponding to PFS
| Outcome categories | Overall | Treatment arm |
||
|---|---|---|---|---|
| A | F | G | ||
| No. (%) | No. (%) | No. (%) | No. (%) | |
| Total* | 1419 | 390 | 670 | 359 |
| 1) Progression and death | 1229 (86.6) | 353 (90.5) | 557 (83.1) | 319 (88.9) |
| 2) Death without progression | 80 (5.6) | 20 (5.1) | 43 (6.4) | 17 (4.7) |
| 3) Progression and censored prior to death | 74 (5.2) | 0 (2.6) | 50 (7.5) | 14 (3.9) |
| 4) Censored prior to progression or death | 36 (2.5) | 7 (1.8) | 20 (3.0) | 9 (2.5) |
*
Censoring was performed administratively at 60 months. Treatment arm A: 5-FU/LV (5-fluorouracil and leucovorin) with CPT-11 (irinotecan); treatment arm F: 5-FU/LV with OXAL (oxaliplatin); treatment arm G: OXAL with CPT-11. PFS = progression-free survival.